Breakthrough Method Enables Drug Delivery Across Blood-Brain Barrier

Researchers at Mount Sinai have developed a novel blood-brain barrier-crossing conjugate (BCC) platform that uses γ-secretase-mediated transcytosis to deliver large therapeutic molecules into the brain. This system successfully silenced harmful genes linked to ALS and Alzheimer's in mouse models and human brain tissue, offering a promising new approach for treating neurological disorders. The BCC platform could revolutionize drug delivery to the central nervous system, overcoming a major challenge in brain research.